Two people. Nearly two billion in projected sales. Telehealth built like a meme account and scaled like a freight train. Also - an FDA warning letter.
My AI research agent pulled the raw docs - FDA letter, Business Insider, STAT, NYT - and the pattern is loud. This is MEDVi, LLC in Delaware doing GLP-1 weight-loss telehealth. Not MEDvidi in California. Not the Canadian MedVi.
Core idea - make GLP-1 care internet-native: click, quick intake, virtual visit, compounded meds shipped. Built in about two months using AI, roughly $20k to start, then plugged into outside provider networks instead of hiring a big team. As of 2026, reports say two employees and no venture money.
Why it worked - America wanted semaglutide and tirzepatide yesterday. Shortages, high prices, and slow clinics made people try web-first options. Medvi stripped friction, pushed speed, and let affiliates and social do the loud work. Automation handled marketing, support, and parts of ops; contracted clinicians did the visits.
Founder story - Matthew Gallagher calls it vibe-coding with AI: ChatGPT-style tools for the site, AI-generated ad creative, AI agents in support. Product is web-first - intake, televisit, meds shipped. Reporting points to white-label medical groups behind the scenes and compounders making the drugs. Specific code or cloud details aren’t public.
Numbers - about $400M revenue and roughly $65M profit in 2025, with nearly $2B in 2026 projected sales - all with two people. No audited filings or public valuation. Treat it as a claim, not gospel.
The catch - in Feb 2026 the FDA warned MEDVi, LLC for misbranding tied to compounded GLP-1s and sketchy labeling on an affiliate domain. Medvi says it was an unauthorized partner and they shut it down. Still, platforms and regulators usually hold the brand responsible. Add lawsuits and spam complaints. And remember: compounded drugs aren’t FDA-approved, so the ice is thin.
Takeaway - AI plus outsourcing can turn a scooter into a rocket. In healthcare, speed without tight compliance is a hand grenade. If you copy this: lock down affiliates, name your clinical and pharmacy partners, publish pricing, show outcomes, and actually own the patient experience.
So - is Medvi a glimpse of the future of care delivery, or just arbitrage that melts when regulators and big brands catch up? Would you let affiliates sell medicine under your logo? ⚡️